Unknown

Dataset Information

0

Acetylated Benzothiazolone as Homobivalent SPECT Metallo-Radiopharmaceutical 99mTc-(6-AcBTZ)2DTPA: Design, Synthesis, and Preclinical Evaluation for Mapping 5-HT1A/7 Receptors.


ABSTRACT: Mapping different structural forms of serotonin subtypes 5-HT1A-5-HT7 using a selective-specific ligand with good pharmacokinetics and brain permeability can open avenues for personalized medication in depressed population. Herein, the selective 5-HT1A/7 antagonist, modified for enhanced brain permeation, is developed as a homobivalent ligand, (6-AcBTZ)2DTPA. After in-depth computational studies to probe the binding mechanism, two-step synthesis lead to (6-AcBTZ)2DTPA. Biocompatibility studies indicated cytocompatibility with 3.6-1.64% cell death (0.1 mM-1 pM) and hemocompatibility with 2.33% hemolysis of human erythrocytes. When 99mTc-radiolabeled in a quantitative yield (98%), a stable preparation was obtained with 7.4 and 3.5% dissociation upon incubation with human serum and excess cysteine. The single-photon-emission computed tomography (SPECT) tracer 99mTc-(6-AcBTZ)2DTPA showed biphasic clearance (t 1/2, distribution = 0.5 min and t 1/2, elimination = 482 min) and maximum brain uptake of 0.42 ± 0.02% ID/g with the regional localization (hippocampus: 11.38% ID/g; cortex: 26.42% ID/g; cerebellum: 25.23% ID/g). Thus, the 99mTc-metal-based SPECT neurotracer holds potential for neuroreceptor mapping.

SUBMITTER: Jha P 

PROVIDER: S-EPMC6647941 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Acetylated Benzothiazolone as Homobivalent SPECT Metallo-Radiopharmaceutical <sup>99m</sup>Tc-(6-AcBTZ)<sub>2</sub>DTPA: Design, Synthesis, and Preclinical Evaluation for Mapping 5-HT<sub>1A/7</sub> Receptors.

Jha Preeti P   Chaturvedi Shubhra S   Anju   Kaul Ankur A   Jain Nidhi N   Mishra Anil K AK  

ACS omega 20190610 6


Mapping different structural forms of serotonin subtypes 5-HT<sub>1A</sub>-5-HT<sub>7</sub> using a selective-specific ligand with good pharmacokinetics and brain permeability can open avenues for personalized medication in depressed population. Herein, the selective 5-HT<sub>1A/7</sub> antagonist, modified for enhanced brain permeation, is developed as a homobivalent ligand, (6-AcBTZ)<sub>2</sub>DTPA. After in-depth computational studies to probe the binding mechanism, two-step synthesis lead t  ...[more]

Similar Datasets

| S-EPMC11519562 | biostudies-literature
| S-EPMC8324619 | biostudies-literature
| S-EPMC9984322 | biostudies-literature
| S-EPMC4025745 | biostudies-literature
| S-EPMC11312272 | biostudies-literature
| S-EPMC9146797 | biostudies-literature
| S-EPMC9658561 | biostudies-literature
| S-EPMC10610005 | biostudies-literature
| S-EPMC6338786 | biostudies-literature
| S-EPMC5827335 | biostudies-literature